Navigation Links
IRIDEX Corporation Announces Preliminary Results of its Tender Offer
Date:12/10/2012

MOUNTAIN VIEW, Calif., Dec. 10, 2012 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) announced today the preliminary results of its tender offer to purchase up to 487,500 shares of its common stock at a purchase price of $4.10 per share, which expired at 5:00 p.m., New York City time, on Friday, December 7, 2012. Based on the preliminary count by Computershare Inc., the depositary for the tender offer, an aggregate of 1,447,141 shares of common stock were properly tendered and not withdrawn, including 14,060 shares that were tendered through notice of guaranteed delivery. Accordingly, IRIDEX expects to accept for purchase an aggregate of 487,500 shares of its common stock at a purchase price of $4.10 per share.These shares represent approximately 5.5 percent of IRIDEX's currently issued and outstanding shares of common stock.

Because the tender offer was oversubscribed, the number of shares that IRIDEX will purchase from each tendering stockholder will be pro-rated. Based upon the preliminary count by the depositary, IRIDEX estimated that the pro-ration factor will be approximately 33.6%, assuming all shares tendered through notice of guaranteed delivery procedures are properly delivered, or approximately 34%, excluding all shares tendered pursuant to guaranteed delivery procedures.  The number of shares properly tendered and not withdrawn and the pro-ration factor are preliminary and are subject to: confirmation by the depositary of the proper delivery of the shares properly tendered and not withdrawn and the impact of odd-lot tenders. The actual number of shares properly tendered and not withdrawn and the pro-ration factor will be announced following the completion of the confirmation process. Payment for the shares accepted for purchase and return of all other shares tendered will occur promptly thereafter. Payment for shares will be made in cash, without interest.

The tender offer was made pursuant to an Offer to Purchase, dated November 7, 2012, as amended by Amendment No. 1 to the Offer to Purchase, dated November 13, 2012, and Letter of Transmittal, dated November 7, 2012, filed with the Securities and Exchange Commission.

The information agents are The Proxy Advisory Group, LLC and Allen & Caron Inc., and the depositary is Computershare Inc. For questions and information, please call the information agents toll-free at (888) 740-7130.

Forward-Looking Statements

This press release contains forward-looking statements, as defined under the federal securities laws. These forward-looking statements include statements regarding IRIDEX's expectation regarding the number of shares to be purchased, the pro-ration factor and the completion of the tender offer and payment for the shares. These forward-looking statements are not guarantees and are subject to risks, uncertainties and assumptions that could cause the actual number of shares to be purchased, the pro-ration factor and the timing for the completion of the tender offer and payment for the shares to differ materially and adversely from the number expressed in the forward-looking statements in this press release. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as to IRIDEX's expectations as of the date hereof.  IRIDEX undertakes no obligation to update these forward-looking statements as a result of events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE IRIDEX Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. IRIDEX Announces FDA 510(k) and CE Clearance of New Laser Delivery System for Fast, Non-invasive Treatment of Serious Retinal Diseases
2. QUANTEL Medical Signs Global Licensing Agreement with IRIDEX
3. IRIDEX Announces Tender Offer to Purchase up to 487,500 Shares of its Common Stock
4. IRIDEX Reports 2012 Third Quarter Results
5. IRIDEX Announces Third Quarter 2012 Conference Call and Release Date
6. IRIDEX Appoints Chairman William M. Moore as Interim President & CEO
7. IRIDEX Reports 2012 Second Quarter Results
8. IRIDEX Announces Second Quarter 2012 Conference Call and Release Date
9. IRIDEX Reports 2012 First Quarter Results
10. IRIDEX Introduces Non-Invasive MicroPulse™ Therapy for Glaucoma
11. SafeCode Drug Technologies Corporation Identifies the Technology Group to Commence and Develop the Worlds First Prototype for its Next Generation Application for Drug Safety Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... PUNE, India , January 24, 2017 ... Allied Market Research, titled, "Cold Chain Logistics Market by ... & Frozen Dessert, Meat, Fish & Sea Food, Drugs ... Industry Forecasts, 2014-2022," projects that the global cold chain ... 2022, growing at a CAGR of 16% (2016 to ...
(Date:1/24/2017)... January 24, 2017 Analysis of the Liquid ... Liquid Biopsies - our new study reveals trends, R&D progress, ... If you are involved in this sector you must read this ... revenues streams to 2027, assessing data, trends, opportunities and business prospects ... Discover How ...
(Date:1/24/2017)... GAITHERSBURG, Md. , Jan. 24, 2017 /PRNewswire/ ... leader in the engineering and industrialization of biology to improve ... announced that it has entered into a definitive agreement to ... a clinical-stage company and pioneer in the development of AdenoVerse™ ... and expand upon GenVec,s expertise in adenoviral vectors and cGMP ...
Breaking Medicine Technology:
(Date:1/24/2017)... ... ... The University of Iowa, long recognized as one of the top research ... teachers with the specific skills and training they need to teach English as a ... and HigherEducation.com is working to ensure that this new program is available to the ...
(Date:1/24/2017)... CA (PRWEB) , ... January 24, 2017 , ... The ... good news for everyone and particularly good news for prostate cancer patients: incidents of ... diagnosis. , According to the report the cancer death rate has dropped from its ...
(Date:1/24/2017)... Pass, OR (PRWEB) , ... January 24, 2017 ... ... Gerald H. Pollack, Ph.D., http://www.faculty.washington.edu/ghp , Sharon Kleyne, the nation’s foremost ... of Water, Global Climate Change and Your Health on Voice America, once again ...
(Date:1/24/2017)... ... January 24, 2017 , ... ... unveiled its latest award-winning bottles, designed specifically to optimize the drinking experience for ... Agua is renowned for introducing the world’s first untouched bottled water purposed exclusively ...
(Date:1/24/2017)... (PRWEB) , ... January 24, 2017 , ... ... a leading natural supplement for relieving premenstrual syndrome, or PMS . , ... some point. These symptoms can include cramps, constipation, irritability, headaches, fatigue, and other ...
Breaking Medicine News(10 mins):